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ABSTRACT
Spyl is a cell cycle activator, known to mediate cell cycle progression through an
atypical activation of the cyclin dependent kinases. To understand the development and
progression of breast cancer it is essential to elucidate the mechanisms and interactions of
normal regulators of breast development. This study demonstrates that endogenous Spyl
protein and mRNA levels are tightly regulated during normal mammary gland
development; being expressed during proliferative stages and downregulated at the onset
of lactation. This appears to be regulated, in part, through the oncogene c-Myc and the
MAPK signaling pathway. Importantly, we show that aberrant expression of the Spyl
protein prevents normal differentiation and results in disrupted morphology of the gland
as well as tumorigenesis. Collectively this work has revealed a novel molecular
mechanism regulating normal developmental processes in the breast and has provided
evidence that the Spyl protein may also be implicated in the development of breast
cancer.
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CHAPTER I
INTRODUCTION
Regulation of the Cell Division Cycle; an Overview
The cell division cycle is a delicate and highly controlled process that functions to
control cell division and growth, as well as maintain the integrity of the cell’s genetic
material. Progression through the cell cycle involves four phases: Gapl (G l), DNA
Synthesis (S), Gap2 (G2) and Mitosis (M). Rapid cell growth, duplication of the
organelles and drastic changes in cytosolic volume happen in Gl phase. During late Gl
the cell assesses the available nutrients, growth conditions and its DNA integrity and
decides to either exit or commit to the cell cycle; this is a point referred to as the
restriction point, or the Gl/S checkpoint. If the cell exits the cell cycle, it enters a
stationary phase called quiescence (GO). A quiescent cell remains metabolically active,
and maintains the ability to re-enter the cell cycle when the growing conditions become
favourable. Following successful movement through the restriction point, the cell
replicates the genome in S phase then moves into the second preparatory phase, G2. Here
the cell prepares for entry into M phase by turning on the necessary regulatory proteins
required to initiate mitotic events as well as to monitor DNA integrity and repair any
DNA damage before entering mitosis (Pardee 1989). During M phase replicated DNA
molecules partition into two nuclei, following this event, the entire dividing cell splits in
two daughter cells. The two daughter cells resulting from mitosis possess a genetic
content identical to each other and to the mother cell from which they arose. All these
processes involved in the cell division cycle are tightly regulated at the molecular level
via many different signaling pathways (Pardee 1989).

1

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2

Cell Cycle Regulation by Cvclin-CDK Complexes
Cell cycle progression is regulated by the activity of a family of serine/threonine
protein kinases, called cyclin dependent kinases (CDKs). CDKs are considered the
engines that drive the cell cycle through its various stages. To date, eleven human CDKs
have been identified; these proteins function to phosphorylate many structural and
regulatory proteins required for movement through the cell cycle and successful cell
division (Malumbres and Barbacid 2005).
CDK activity is tightly controlled by specific protein-protein interactions; one
important level of regulation is through the binding of the CDK regulatory subunit,
referred to as cyclin. Cyclin protein concentrations vary from one stage of the cell cycle
to another; being transcriptionally upregulated at specific points and degraded in a
regulatory fashion via ubiquitin mediated proteolysis. Cyclins contain a conserved 100
amino acid region, called cyclin box. The cyclin box is responsible for interaction with
the CDK (Sherr 1994; Morgan 1995; Sherr and Roberts 1999). When cyclins are present
in the cell, they bind to the catalytic subunit of the CDK. This binding causes a major
conformational change within the CDK catalytic subunit resulting in the movement of a
flexible loop of the CDK (the T-loop) away from the enzyme’s active site. This new
conformation allows the CDK to become phosphorylated on a threonine residue (Thrl60
or Thrl61) within the T-loop of the CDK kinase domain by cyclin activating kinase
(CAK). It is now well established that, in order to be in a fully active conformation, a
CDK must also be dephosphorylated on threonine and tyrosine residues (Thrl4 and
Tyrl5) by the CDC25 phosphatases (Jeffrey et al. 1995). Once activated, some CyclinCDK complexes undergo relocalization within the cell. For example, Cyclin B-CDK1 is

2
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Cyclin D-CDK4/6 phosphorylate a number of substrates initiating movement through the
cell cycle; many of these promote the transcriptional regulation of the G l/S phase
cyclins, Cyclin E, and Cyclin A. Cyclins E and A associate with their respective CDK
partner (CDK2) to promote initiation of replication. Activation of Cyclin E-CDK2 is
essential for DNA synthesis at the Gl/S transition. p27 interaction with Cyclin E-CDK2
prevents premature entry into S phase (Nakayama et al. 2001). Normally, p27 protein
levels are high during GO and Gl phases of the cell cycle, resulting in Cyclin-CDK
inhibition. p27 has been found to associate with Cyclin A-CDK2, Cyclin E-CDK2 and
Cyclin D-CDK4,6 (Slingerland and Pagano 2000). Importantly, Cyclin D-CDK4 also
forms a trimeric complex with p27, so less p27 is available to inhibit Cyclin E-CDK2;
and hence this interaction in fact promotes cell cycle movement rather than inhibiting it.
Interestingly, one of the substrates that Cyclin E-CDK2 phosphorylates, is p27. This
phosphorylation occurs at amino acid Thrl87 within p27 and functions to target the CKI
for degradation via the SCFSkp2 (Skp, Cullin, F-box containing complex) ubiquitin ligase
pathway (Pagano et al. 1995; Sheaff et al. 1997; Vlach et al. 1997; Carrano et al. 1999;
Montagnoli et al. 1999; Sutterluty et al. 1999; Tsvetkov et al. 1999). Decreased protein
levels o f p27 allows progression into S phase. In general, the SCF complex acts through
out the cell cycle and mediates the degradation of other CKIs, as well as G l cyclins and
cell cycle proteins.
Molecular Controls over the G2/M Transition and Progression through Mitosis
The G2/M transition and M phase progression are primarily regulated via
activation of both Cyclin A-CDK1 and Cyclin B-CDK1 complexes. These cyclins are
synthesized and associate with CDK1 in late S phase and early G2 respectively, but the

4
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complexes remain inactive due to the inhibitory phosphorylation o f CDK1 on the key
threonine and tyrosine residues (Thrl4 and Tyrl5) by M ytl. Phosphorylation o f CDK1
on Thrl61 by CAK, and dephosphorylation by the CDC25 phosphatase family occurs at
early G2 for Cyclin A-CDK1 and in late G2 for Cyclin B-CDK1. The active CyclinCDK1 complex phosphorylates a diverse range of proteins responsible for G2/M
transition, M phase entry and progression through M phase; such as cytoskeletal proteins,
histones and proteins o f the nuclear envelope. By the end of mitosis, the cyclin separates
from CDK1, and a phosphatase removes the phosphate group from Thrl61. The free
cyclin becomes degraded via the anaphase promoting complex or APC complex. APC
acts in mitosis and degrades mitotic proteins, including mitotic cyclins. Destruction of
cyclins A and B is a key factor in the inactivation of CDK1 and the transition of the cell
from mitosis back into Gl (Coleman and Dunphy 1994).

5
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CHAPTER II
REVIEW OF LITERATURE
Isolation and Characterization of Xenopus Speedy
Xenopus Speedy or X-Spyl was first identified in a genetic screen utilizing a
Xenopus Laevis ovary cDNA library to isolate novel genes which conferred resistance to
UV radiation using a radl-deficient strain of the fission yeast, Schizosaccharomyces
pombe (Lenormand et al. 1999). radl is a cell cycle checkpoint gene which arrests the
cell at G2/M in the presence of DNA damage or in the absence of complete DNA
replication (al-Khodairy and Carr 1992). Loss of radl function causes cell death
following DNA damage (Hartwell and Weinert 1989). This initial discovery prompted
researchers to believe that Spyl was involved in the DNA damage response. Immediately
following the publication of X-Spyl, another group reported the isolation o f two isoforms
of a gene they entitled, Xenopus RINGO or X-RINGO (Rapid Inducer of G2/M Ooctye
Maturation). X-RINGO was identified using an expression cloning strategy to identify
novel proteins involved in G2/M progression in Xenopus oocytes. The two isoforms of XRINGO are 88% identical to one another and one of the isoforms shows 99% identity
with X-Spyl (Porter et al. 2002). Throughout this thesis the latter form of X-RINGO will
be referred as X-Spyl.
Xenopus oocytes are naturally arrested in late G2 and G2/M boundary o f the first
meiotic division. Progesterone stimulation is known to overcome oocytes arrest and
promote progression of the oocytes through meiosis. This process, known as meiotic
maturation, results in germinal vesicle break down (GVBD) and activation o f the Cyclin
B1-CDK1 complex, also referred to as the maturation promoting factor (MPF). Oocytes

6
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enter into meiosis I, then arrest again at metaphase of meiosis II until fertilization (Sagata
1997). X-Spyl expression in oocytes, either as synthetic mRNA or recombinant protein,
induces MPF activation and GVBD in the absence of progesterone. Furthermore,
introducing antisense oligonucleotides against X-Spyl into oocytes is able to delay
progesterone-induced oocyte maturation. This demonstrates that X-Spyl expression in
G2 arrested oocytes is required for progesterone-induced oocyte meiotic maturation
(Ferby et al. 1999). Also, X-Spyl over-expression induces oocyte meiotic maturation
faster than progesterone (Ferby et al. 1999; Lenormand et al. 1999). X-Spyl deletion
mutants show that amino acids 54-218, a highly conserved central region coined the
“Spyl/RINGO box”, is essential for induction of oocyte maturation; whereas the amino
and carboxy termini of the protein are dispensable for this function (Porter et al. 2002).
Previous studies have suggested that progesterone-induced maturation can be
activated by the mos proto-oncogene, as injection of specific antisense mos
oligonucleotide into oocytes blocks progesterone-induced GVBD (Sagata 1997).
Hormonal activation of prophase arrested oocytes leads to activation of the mitogen
activated protein kinase pathway (MAPK pathway) (Nebreda and Hunt 1993). It has been
proven that progesterone induces oocytes by stimulating the translation of Mos protein,
which is a MAP kinase kinase kinase (MAPKKK). Mos in turn leads to activation of the
MAP kinase kinase, MEK (Sagata 1997). Interestingly, antisense mos oligonucleotides
failed to block Spyl-induced GVBD, indicating that mos is not required for Spylinduced maturation (Lenormand et al. 1999). Further experiments have shown that, when
activation of MEK was blocked using a MEK antibody, X-Spyl-induced maturation was
inhibited too. Furthermore, recombinant X-Spyl can trigger GVBD and MPF activation

7
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even in the presence of the MEK protein synthesis inhibitor PD98059. This information
together, suggests that X-Spyl is under regulation of MEK through MAPK pathway
(Ferby et al. 1999; Lenormand et al. 1999). Further studies suggest that X-Spyl induces
rapid meiotic maturation through the MAPK pathways and this in turn causes rapid
activation of MPF through a premature activation of CDK2 (Lenormand et al. 1999).
Although X-Spyl does not show amino acid sequence homology to cyclins, studies show
that Spyl both binds to and activates CDK1 and CDK2 independent o f cyclin binding
(Ferby et al. 1999; Lenormand et al. 1999; Karaiskou et al. 2001). Interestingly, both XSpyl and RINGO bind and activate CDK2 in a p21-independent manner (Ferby et al.
1999; Lenormand et al. 1999). Also, it has been reported that the activation of CDK2
does not rely on the phosphorylation of the CDK at residue Thrl61 (Karaiskou et al.
2001). Collectively this demonstrates that Spyl is capable of activating CDKs utilizing a
novel mechanism.
Regulation of Xenopus -Spyl Protein Levels
Endogenous X-Spyl expression is tightly regulated during the meiotic cell cycle.
At the onset of meiosis I entry, X-Spyl protein levels are increased transiently and then
decrease significantly between meiosis I and meiosis II. This tight regulation is via the
ubiquitin proteasome system (UPS) at two different levels, processing and degradation.
X-Spyl has been shown to be processed into X-RINGOSp (for X-RINGO small and
processed) by the joint activity of two kinases that are active in G2-arrested oocytes
named, protein kinase A (PKA), glycogen synthase kinase-3P (GSK-3P), and the
ubiquitin ligase pTrCP (SCFpTrCP). The DSGXXS motif is considered to be the pTrCP
recognition motif; however certain pTrCP substrates such as CDC25A or Weel A contain

8
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several functional motifs involved in (3TrCP recognition (Watanabe et al. 2004; Kanemori
et al. 2005; Watanabe et al. 2005). In the case of X-Spyl, a canonical DSGXXS motif
acts as the major PTrCP recognition motif, however phosphorylation by PKA and GSK3p create additional recognition sites. X-Spyl is also degraded by the UPS after GVBD.
This event requires the activity of mitotic kinases and the RING-finger ubiquitin ligase
Siah-2. Recognition of the substrates by Siah-2 ubiquitin ligase does not require specific
phospohrylation of the substrates. However, X-Spyl phosphorylation on Ser 243 is
necessary for X-Spyl recognition by Siah-2 and X-Spyl downregulation after meiosis I.
Ser243 residue on X-Spyl is a potential target for CDK2 phosphorylation. Maybe CDK2,
which accumulates during oocyte maturation, regulates X-Spyl protein levels via a
negative feed back loop. Interestingly, failure to initiate X-Spyl down regulation causes
DNA synthesis during the meiosis I- meiosis II transition (Gutierrez et al. 2006). This
data implicates X-Spyl in altering DNA integrity during early stages of development,
which may implicate Spyl in the early initiation of carcinogenesis.
Regulation of Xenopus -Spyl RNA Levels
As is the case for many proteins involved in Xenopus oocyte maturation, X-Spyl
mRNA has been shown to remain dormant in the resting oocyte and to be rapidly
translated soon after the induction of meiotic maturation. It is possible that in addition to
regulation by protein processing and degradation, de-repression of X-Spyl mRNA
translation contributes to X-Spyl accumulation during Xenopus oocyte maturation
(Padmanabhan and Richter 2006). One of the highly regulated events that occur during
vertebrate oocyte maturation is the maternal mRNA translation of early genes such as,
MAPK, MPF and Mos. For instance, Mos and cyclin mRNA translation is regulated by

9

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

10

cytoplasmic polyadenylation, which requires the cytoplasmic polyadenylation element
(CPE) in the 3’UTR of these genes. CPEB, cytoplasmic polyadenylation element binding
protein, is a sequence specific RNA binding protein. It binds to CPE and regulates the
translation of maternal mRNA via polyadenylation of the maternal mRNA.
Polyadenylation-stimulatory activity of CPEB is controlled by Aurora A-catalyzed S I74
phosphorylation. It also interacts with various factors to stimulate polyadenylation. In
addition to polyadenylation, CDK activity is also necessary for the activation of the MosMAPK and MPF pathways during meiotic maturation. There is a possibility that a small
amount of Cyclin B1 mRNA translates soon after progesterone induction. The
synthesized Cyclin B protein induces CDK activity that, in turn stimulates CPEBmediated polyadenylation. It has been demonstrated that over expression o f X-Spyl in
oocytes rapidly induces Mos synthesis, as well as MAPK and MPF activation and XSpyl binds and activates CDK1 and CDK2 (Littlewood et al. 1995; Ferby et al. 1999).
This information suggests that, X-Spyl may associate with free CDK1 in oocytes and
activate MPF. Also, it is possible that the translation of X-Spyl activates CPEB. Studies
determine not only the necessity of X-Spyl protein for CPEB-mediated polyadelynation
during meiotic maturation of oocytes, but also the mechanism by which X-Spyl mRNA
translation is controlled. X-Spyl synthesis precedes and it is required for CPEB
phosphorylation and other downstream effects such as Mos mRNA polyadenylation and
translation. In immature oocytes, a region of the 3’UTR that includes Pumilio 2-Binding
Elements (PBEs) represses X-Spyl mRNA translation. One of the proteins that associate
with PEB is Pum2. Oocyte injection with either Pum2 antibody or dominant negative
form of Pum2 protein stimulates X-Spyl synthesis and oocyte maturation. Progesterone

10
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treatment of oocytes dissociates Pum2 from X-Spyl mRNA, which in turn results in XSpyl mRNA translation. It is suggested that Pum2-mediated translation of X-Spyl
mRNA is required for CPEB activation.
Isolation and Characterization of Human Speedy (Spyl)
A database search for other Spyl homologs yielded a human EST clone from a
testis cDNA library with 63% homology over a 170 bp region of X-Spyl. Using PCR
based serial dilution cloning method; the first full length human homologue of Speedy
gene was isolated from a human testis cDNA library. The human Spyl (Spyl) cDNA
clone is a 1300 bp sequence, and encodes for a polypeptide containing 286 amino acids.
Spyl shows an overall 40% homology to X-Spyl, including a highly conserved 150
amino acid region with 70% homology (Porter et al. 2002). Spyl mRNA microinjection
in Xenopus oocytes induced maturation in the absence of progestrone, albeit less
efficiently than X-Spyl (Porter et al. 2002). Spyl mRNA is expressed in multiple human
tissues and immortalized cell lines (Porter et al. 2002; Cheng et al. 2005b). Further
investigation has demonstrated that Spyl is regulated in a cell cycle-dependent manner
and it is highly expressed at Gl/S transition. Spyl is localized in nucleus; it interacts with
CDK2 independent of cyclin binding and stimulates CDK kinase activity in mammalian
cells. Overexpression of Spyl increases cell proliferation. More precisely, cells
overexperessing Spyl show significant increases in both DNA replication events and
mitochondrial activity. These findings indicate that Spyl expressing cells are undergoing
cellular replication at a higher rate. Interestingly, Spyl overexpression has no affect on
cellular proliferation when CDK2 kinase activity is inhibited. Depleting endogenous
Spyl using small interfering RNA (siRNA) directed against Spyl, significantly decreases

11
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cell proliferation as well as CDK2 kinase activity. Moreover, RNAi knockdown of Spyl
prevented cellular proliferation by inhibiting efficient S-phase entry (Porter et al. 2002).
Thus, endogenous Spyl is an essential protein in normal cell growth.
Using full length Spyl as bait in a yeast two-hybrid screen identified p27 as a
binding partner for Spyl. p27 is a CKI from Cip/Kip family which functions in the
nucleus to inhibit the Cyclin E-CDK2 complex and prevent premature activation of this
kinase and premature entry into S phase (Reynisdottir and Massague 1997; Slingerland
and Pagano 2000; Nakayama et al. 2001). As mentioned above, one of the substrates of
Cyclin E-CDK2 is p27. p27 is phosphorylated on Thr 187 as a result o f activated CDK2.
This phosphorylation at Thrl87 targets p27 for degradation via the SCFskp2 ubiquitin
ligase pathway. Finally, decreasing p27 protein levels results in cell cycle progression
through Gl/S transition. (Pagano et al. 1995; Morisaki et al. 1997; Sheaff et al. 1997;
Vlach et al. 1997; Carrano et al. 1999; Montagnoli et al. 1999; Sutterluty et al. 1999;
Tsvetkov et al. 1999). This dichotomy highlights the importance of studying alternative
ways of activating CDK2; hence Spyl may represent a novel mechanism of relieving p27
inhibition over CDK2 and will ultimately promote the degradation of p27. Along these
lines, more detailed studies demonstrate that endogenous Spyl and endogenous p27
interact in vivo. Spyl binds to the CDK-binding region of p27, but not the cyclin binding
region of p27. Studies also demonstrate that Spyl, CDK2 and p27 can form a trimeric
complex, in which increased levels of p27 cause increased association of Spyl with the
complex and that CDK2 binding to Spyl is enhanced in the presence of p27.
Mechanistically, Spyl overcomes a p27-induced Gl arrest by restoring CDK2 kinase
activity via degradation of p27 (Porter et al. 2003). Furthermore, p27 null cells show the

12
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same proliferation rate as Spyl over expressing cells demonstrating that Spyl-induced
proliferation depends on p27 degradation. This raises the possibility that Spyl enhances
cell cycle progression by preventing the inhibitory actions of p27 on CDK2. Collectively
these results demonstrate that Spyl plays a key role in regulating p27 inhibition of
CDK2, and hence plays a primary role in promoting cell cycle progression through the
Gl/S checkpoint (Porter et al. 2003).
Role o f Spyl in the DNA Damage Response
In the fission yeast, Schizosaccharomyces pombe, radl is known to be one of the
genes required for checkpoint control in the presence of DNA damage or in the absence
of complete DNA replication (al-Khodairy and Carr 1992; al-Khodairy et al. 1994). As
mentioned previously, X-Spyl rescues the radl-deficient fission yeast mutant strain from
apoptosis following both ultraviolet irradiation (UV) and y-radiation treatments,
suggesting that X-Spyl complements a radl deficiency in yeast (Lenormand et al. 1999).
To investigate whether Spyl plays a role in the DNA damage response in mammalian
cells a series o f experiments were conducted. These results demonstrated that Spyl over
expression increases cell survival after induction of DNA damage via different genotoxic
agents such as camptothecin (CPT), cisplatin and hydroxyurea (HU) treatments.
Furthermore it was demonstrated that survival effects were abolished when Spyl was
knocked down via siRNA (Barnes et al. 2003). Clonogenic survival assays in the
presence o f CPT show that Spyl over expression increases cellular viability long term;
suggesting that Spyl is not simply overcoming an essential DNA checkpoint (Barnes et
al. 2003). Measuring fragmented DNA after CPT treatment o f mammalian cells using an
alkaline comet assay also shows that Spyl over expression decreases DNA fragmentation

13
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following damage. These results could indicate a decrease in damage to the DNA or it
could indicate a decrease in the number of cells undergoing apoptosis (Barnes et al.
2003). Interestingly, the survival effect of Spyl decreases upon expression of a CDK2
dominant negative mutant indicating that, Spyl must both bind to and activate CDK2 in
order to induce cell survival under genotoxic stress (Barnes et al. 2003). It has also been
shown that endogenous levels of Spyl protein are upregulated after CPT, cisplatin and
HU treatments of mammalian cells. Taken together, theses results clearly indicate that
Spyl protein expression mirrors the expression of several checkpoint proteins, such as
E2F, p53 and p21, which are upregulated after genotoxic stresses (Kastan et al. 1991;
Blattner et al. 1999).
While the above-mentioned experiments reveal a role for Spyl in protecting the
cell from death following DNA damage they tell us little about the mechanism by which
this is occurring. To investigate this mechanism further investigators have studied the
role of Spyl following UV radiation. Various flow cytometry experiments show that
Spyl expression inhibits apoptosis in response to UV radiation. These effects were
shown to occur because Spyl inhibits activation of pro-apoptotic pathways (Gastwirt et
al. 2006). Also, Spyl expression allows for UV irradiation resistant DNA synthesis and
permits cell progression to mitosis in the presence of DNA damage. These results
indicate that Spyl inactivates both Gl/S and G2/M checkpoints in response to DNA
damage (Gastwirt et al. 2006). Further studies demonstrate that Spyl inhibits activation
of checkpoint proteins such as Chkl, RPA32 and the histone variant H2A.X in response
to UV irradiation. Mutations within the Speedy/RINGO box of Spyl, known to mediate
the interaction with and activation of CDK2 (Cheng et al. 2005b; Dinarina et al. 2005),
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prevent inactivation of Chkl and RPA32 in response to UV induced DNA damage. Thus,
Spyl-CDK2 interaction is essential for Spyl-mediated DNA damage effects, but not
Spyl-induced proliferation (Gastwirt et al. 2006). Collectively these experiments suggest
that Spyl is functioning to inhibit specific apoptotic events following DNA damage; an
activity that may be harmful for long-term growth effects of the cell.
Speedy/RINGO Protein Family
Investigations into Spyl homologues have suggested that these proteins are
members of a novel protein family (Cheng et al. 2005b; Dinarina et al. 2005). Speedy like
genes have been identified in the most primitive branching clade of chordates (Ciona
intestinalis), demonstrating that they are well conserved among vertebrates (Cheng et al.
2005b). Recently, speedy like genes have been placed in a large family of vertebrate
proteins designated the Speedy/RINGO family. Speedy/RINGO family o f vertebrate cell
cycle regulators, control cell proliferation and cell survival through the atypical activation
o f CDKs.
In mammals there are at least five functional isoforms of Speedy; two SpeedyA
(SpeedyAl and SpeedyA2), SpeedyB, SpeedyC, and SpeedyD. It has been suggested that
the two isoforms of SpeedyA are the result of spliced variants. SpeedyAl and SpeedyA2
have been identified in both Homo sapiens (chromosome 2) and Mus musculus
(chromosome 17). SpeedyAl is widely expressed in many tissues and cell lines. SpeedyB
has been identified in Mus musculus (chromosome 5) and it is testis specific. SpeedyC
has been identified in Homo sapiens (chromosome 11) and is expressed specially in
tissues that undergo polyploidy. SpeedyD has also been identified in Mus musculus
(Cheng et al. 2005b). Although Speedy expression patterns differ throughout the body,
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testis is considered a Speedy enriched tissue, as it expresses all known forms of Speedy in
high levels. This is consistent with the X-Spyl functions during meiosis (Cheng et al.
2005b).To simplify the nomenclature Spyl will be used throughout this thesis to
represent human SpeedyAl; any other isoform of Spyl will be written out in full and any
other species will be represented by a hyphenated letter in front of the protein/gene.
The members of the Speedy/RINGO family share high sequence homology
within a central region known as the Speedy/RINGO box (S/R Box). Speedy/RINGO box
is a conserved region of around 100 amino acids which is essential for CDK2 binding and
activation (Cheng et al. 2005b; Dinarina et al. 2005). Spyl and its homologs activate
CDK2 in the absence of known mechanism of activation (Cheng et al. 2005b). Both
mammalian SpeedyA and C bind to CDK1 and CDK2. Mammalian SpeedyB binds
preferably to CDK1. Interestingly, both SpeedyA and B promote Xenopus oocyte
maturation, even though they bind preferentially to different CDKs (Cheng et al. 2005b).
Mutations in the Speedy/RINGO box abrogate both CDK binding and oocyte maturation
(Dinarina et al. 2005). In addition to the central Speedy/RINGO box, the C-terminal
region of SpeedyA promotes CDK activation, whereas the N-terminal region influences
Spyl protein expression (Cheng et al. 2005b).
Moreover, it has been shown that CDK2 complexed with the SpeedyA2 isoform
displays broader substrate specificity in comparison to CyclinA-CDK2. CDK2-SpeedyA2
prefer noncanonical CDK2 substrates such as a KSPRY peptide or the CDC25
phosphatases which contain non-canonical CDK phosphorylation sites (Cheng et al.
2005a)
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The Mammary Gland as a Model System for Development and Cancer
Our research group and others’ have determined that Spyl protein levels are
elevated in many aggressive forms of cancer, including invasive ductal carcinoma of the
breast (Zucchi et al. 2004). For this reason we have focused on characterizing the
molecular pathways regulating Spyl protein levels in the proliferating mammary gland.
Proliferation of the mammary gland is a normal step in development; occurring
periodically both during embryogenesis as well as throughout the life of the organism.
One o f the principal objectives of my research is to understand the role of Spyl in normal
mammary gland development, and to determine potential alterations that happen in breast
cancer. In addition, the developing mammary gland is an ideal model system for studying
genes involved in cell cycle regulation because it is one of the few organs that undergoes
cycles o f proliferation, differentiation and apoptosis throughout the life of the organism
and it is not essential for the viability of the animal, making manipulation of the gland
feasible.
Mouse mammary gland development begins at embryonic day 11 by formation of
5 mammary placodes along the two milk lines. These placodes form the epithelial buds
within one day. At embryonic day 15.5, each epithelial bud elongates by invasion into the
mammary fat pad and forms a sprout. Each sprout forms a lumen that opens to the skin
surface and the nipple forms. At embryonic day 16 the first branching o f the sprout
occurs, and by embryonic day 18.5 the sprouts have developed into small tree like glands
(Veltmaat et al. 2003). After birth, the mammary gland grows isometrically with body
growth. At puberty, different hormones induce differentiation and the mammary gland
starts to grow allometrically. Pubertal mammary gland development is driven by the
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changes occurring in the terminal end buds (TEBs). TEBs are highly proliferative
structures which drive ductal elongation and invade into the mammary fat pad (Ball
1998).
At a molecular level, embryonic development of the mammary gland is dependent
on epithelial-mesenchymal signaling (Hennighausen and Robinson 2001). In vivo studies
show that after the embryonic and prepubertal stages of mammary gland, further
development of the gland becomes hormone dependent. At the onset of puberty
epidermal growth factor (EGF) signals through the mammary gland stroma and controls
early ductal outgrowth. Different hormone depletion studies have revealed specific
steroid hormones that regulate mammary gland development. In addition to EGF,
hormones such as estrogen stimulate rapid proliferation, and, together with progesterone,
promote extensive lateral branching of mammary gland epithelia (Medina 1996). It is
well known that estrogen acts directly on the mammary gland and stimulates ductal
elongation and branching during puberty (Silberstein et al. 1994). Further studies link
estrogen action with the cell cycle machinery demonstrating a role for estrogen in the
Gl/S transition (Osborne et al. 1984; Leung and Potter 1987a; Leung and Potter 1987b;
Altucci et al. 1996; Foster and Wimalasena 1996; Planas-Silva and Weinberg 1997; Prall
et al. 1998). In this stage of development, estrogen binds to estrogen receptors (ERs),
which are members of nuclear receptor super family of transcription factors. The
estrogen-ER complex then regulates transcription o f target genes via binding to DNA
enhancer elements located in the promoter regions directly or in association with other
coregulators (Bocchinfuso and Korach 1997b; Bocchinfuso and Korach 1997a; Weihua et
al. 2003). It is also known that estrogen has a rapid and direct effect on regulation o f the
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transcription factor c-Myc (Dubik et al. 1987). Strong evidence places c-Myc among the
key players in mediating estrogen action (Watson et al. 1991; Prall et al. 1998). This
information makes estrogen a potential candidate in the upstream regulation of Spyl
during mammary gland development.
Early in pregnancy, epithelial cells in the quiescent mammary gland respond to
release hormones such as prolactin and placental hormones, and begin to rapidly
proliferate (Traurig 1967). Prolactin is a pituitary peptide hormone that regulates growth
and differentiation of epithelial cells and sustains milk production. Prolactin binds to the
prolactin receptor; resulting in the dimerization and activation of the receptor. This event
in turn stimulates the activation of a receptor associated tyrosine kinase named Janus
Kinase (JAK2) (Darnell et al. 1994; Schindler and Darnell 1995). JAK2 phosphorylates
two members of the transcription factor family o f signal transducers and activators of
transcription (STAT), STAT5A and STAT5B (Ihle 1996). Activated STATs go to the
nucleus and promote expression of target genes by direct binding to DNA via y-interferon
activated sequence. Two y-interferon activated sequences are located in the promoter of
the milk protein P-casein, and this protein is upregulated by STAT5 (Schmitt-Ney et al.
1991; Burdon et al. 1994). At birth, epithelial differentiation occurs to allow lactation
(Robinson et al. 1995). After weaning, there is a rapid involution of the gland through the
induction of apoptosis (Walker et al. 1989). Studies show that there are other regulatory
signaling pathways including growth factors, proto-oncogenes and tumor suppressors
also involved in mammary gland development at the cellular level (Rosen et al. 1994;
Han et al. 1995; Streuli et al. 1995; Han et al. 1996; Sgambato et al. 1996; Grolli et al.
1997; Baratta et al. 2000; Baratta et al. 2003; Katayama et al. 2003). Among these
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factors, the EGF family of ligands has a significant role in promoting proliferation and/or
differentiation through several signaling pathways. EGF ligands are expressed throughout
the development of the mammary gland (Schroeder and Lee 1998; Sebastian et al. 1998).
These hormones bind to transmembrane tyrosine kinase ErbB receptors. Ligand binding
stimulates receptor dimerization, then activation of tyrosine binding domain. Tyrosine
phosphorylation of the receptor recruits proteins containing a Src homology 2 (SH2)
domain to the receptor. This event causes activation of several proteins via
phosphorylation, including those involved in the MAPK signaling pathway (Boonstra et
al. 1995). EGF receptor also phosphorylates the ER, which in turn leads to ligand
independent activation of ER to mediate estrogen induction of end bud formation in the
developing gland (Kato et al. 1995; Bunone et al. 1996; Ankrapp et al. 1998; Tremblay et
al. 1999). Importantly, improper regulation of these signaling pathways can lead to
mammary epithelial hyperplasia and ultimately to mammary gland tumorigenesis
(Engelman et al. 1998).
Cellular Models of Mammary Gland Morphogenesis
At a cellular level mammary epithelial cells have highly definitive morphological
features that are essential for proper cellular function; they have a polarized morphology,
specialized cell-cell contacts and are attached to an underlying basement membrane.
These characteristics contribute toward the function and development of the mammary
gland and disruption of the epithelial cell architecture is a precipitating factor in the
pathogenesis of epithelial tumors (Fauquette et al. 1997).
The HC11 cell line has been employed as a model system to study growth and
differentiation of mammary epithelial cells (Marte et al. 1995; Baratta et al. 2000). These
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cells, originally isolated from normal mid-pregnant BALB/c mice, retain the ability to
differentiate in response to lactation hormones (dexamethasone and prolactin) (Doppler et
al. 1989). Importantly, the HC11 cell line is one of the few non-transformed, clonal
mammary epithelial cell lines that can be utilized in studies of mammary cell
morphogenesis. During differentiation these cells secrete laminin, interact appropriately
with the extracellular matrix and form spherical structures which mimic the
mammospheres formed by primary mouse mammary epithelial cells and acini in the
intact gland (Humphreys and Rosen 1997).

This project focuses around the hypothesis that the novel cell cycle protein Spyl
plays a key role in mammary gland development and breast tumorigenesis. Herein we
describe the regulation of Spyl at protein and mRNA level throughout development of
the mammary gland and we begin to unravel the signaling mechanisms regulating Spyl
expression. Importantly we determine the effects of altering Spyl expression levels on
mammary gland development and we demonstrate a putative role for Spyl in the
development of breast cancer.
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CHAPTER III
DESIGN AND METHODOLOGY
Cell Culture

HC11, BALB/c mouse mammary epithelial cell line (provided by Dr. C.
Shermanko; University o f Calgary) and MCF7, human mammary adenocarcinoma
epithelial cell line (provided by Dr. Andrew V. Hubberstey; University of Windsor) were
maintained in RPMI 1640 medium (Hyclone) containing 10% (vol/vol) fetal calf serum
(Sigma). HC11 cells medium was supplemented with 5 pg/ml insulin (Sigma), and 10
ng/ml EGF (Calbiochem). Myc ER™ MEF, mouse embryonic fibroblast cells (provided
by Dr. G.I. Evan; UCSF) and Phoenix cells (purchased from ATCC) were maintained in
DMEM medium (Sigma) containing 10% (vol/vol) fetal bovine serum (Sigma). Myc
ER™ MEF cells medium was supplemented with 5pg/ml puromycin. HTB125, human
mammary normal cell line and HTB126, human mammary carcinoma cell line (provided
by Dr. S. Pandey; University of Windsor) were maintained in Modified Dulbecco's
medium (Sigma) containing 10% (vol/vol) fetal bovine serum (Sigma). HTB 125 medium
was supplemented with 30 ng/ml EGF (Calbiochem) and HTB 126 medium was
supplemented with 0.01 mg/ml bovine insulin (Sigma). All the cell lines were maintained
in medium containing 2mM L-glutamine (Sigma), penicillin (Invitrogen), and
streptomycin (Invitrogen) and were maintained in a 5% C02 environment.
Plasmids and Constructs
The (3-casein-luciferase construct (provided by Dr. M. David; UCSD) contains
residues -344 to -1 of the P-casein promoter in front of a promoterless luciferase gene.
The promoterless luciferase vector, pSVOAL delta 5’Luc, was constructed using
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pLucDSS vector. This fragment of p-casein promoter is cloned between Hind III/BamHI
restriction sites of pSVOAL delta 5’Luc (Gouilleux et al. 1991; Gouilleux et al. 1994).
The flag-Spyl-pLXSN construct was previously described (Porter et al. 2003). The MycER™ construct (provided by Dr. G. Evan; UCSF) was generated by fusing the 5’ end of
DNA encoding amino acids 281-599 of G525R mutant estrogen receptor to the 3’ end of
DNA encoding amino acids 1-435 of c-Myc to form Myc-ER™. This DNA fragment was
cloned into pBabe-puro (Eilers et al. 1989; Morgenstem and Land 1990a; Morgenstem
and Land 1990b; Danielian et al. 1993; Littlewood et al. 1995)
Stable Cell Lines and Transfections
Flag-Spy 1-pLXSN-HC 11 (Spyl-HCl 1) and pLXSN-HCl 1 (Cntl-HCl 1) stable
cell lines were generated using Phoenix Amphotropic System as previously described
(Kinsella and Nolan 1996; Grignani et al. 1998; Yang et al. 1999). Subconfluent phoenix
cells were treated with 25 pM chloroquine (Sigma) 5 min prior to transfection and then
transfected separately with flag-Spyl-pLXSN and pLXSN using the BBS/calcium
phosphate precipitation method (Chen and Okayama 1987). Infectious flag-Spyl-pLXSN
and pLXSN viruses were collected 48 hr post transfection. HC11 cells were incubated
with retrovirus for 24 hr in the presence of 5 pg/ml polybrene (Sigma). HC11 growth
media was supplemented with the selection antibiotic, 400 pg/ml G418 (Sigma), 48 hr
post infection. G418 resistant clones were selected and maintained in HC11 cell growth
media supplemented with 400 pg/ml G418. Cell lysate of representative clones were
analyzed on 10% polyacrylamide-SDS gels and transferred to PVDF-PLUS transfer
membrane. Expression of flag-Spyl was determined by immunoblotting with both flag
specific monoclonal antibody (Sigma) and Spyl polyclonal antibody.
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Lactogenic Hormone Induced Differentiation
HC11 cells were grown to confluence and maintained for two to three days in
growth media to confer competent cells capable of responding to lactogenic hormones.
To induce differentiation; EGF-containing media was removed, the cells were rinsed
twice with PBS, and then incubated in differentiation media containing R P M I1640
medium, 1% fetal calf serum, 2mM L-glutamine, 5 pg/ml insulin, lpM dexamethasone
(Sigma), 5 pg/ml prolactin (Sigma), penicillin and streptomycin for three days. To assess
differentiation P-casein luciferase was transfected into HC11 cells during the growth
phase using ESCORT™ II Transfection Reagent as suggested by the manufacturer
(Sigma). Luciferase activity was monitored using the Luciferase Assay System
(Promega) and Wallac Victor Reader3 (Perkin Elmer).
Immunoblotting
Total protein was isolated from cell cultures by harvesting cells and lysing in
0.1% NP-40 lysis buffer (5 ml 10% NP-40, 10 ml 1M Tris pH 7.5, 5 ml 0.5M EDTA, 10
ml 5M NaCl up to 500 ml RO water) containing protease inhibitors (10 pl/ml PMSF
stock solution 10 mg/ml, 3 pl/ml aprotinin stock solution 20 mg/ml, 10 pl/ml leupeptin
stock solution 1 mg/ml) for 30 minutes on ice. Total protein was extracted from frozen
mammary gland tissue as previously reported for whole cell extract preparation from
mammary gland (Zahnow et al. 1997). For all protein isolations; Bradford Reagent was
used to determine the concentration of proteins in lysates following the manufacturer’s
instruction (Sigma). Aliquots of lysates containing 20-30 pg protein were subjected to
electrophoresis on denaturing SDS-10% polyacrylamide gels and transferred to PVDFPlus 0.45 micron transfer membranes (Osmonics Inc.) for 3 hr at 30V using a wet transfer
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method. Blots were blocked for 2 hrs in TBST containing 3% non-fat dry milk (blocker)
at room temperature, primary antibodies were reconstituted in blocker and incubated over
night at 4 degrees, secondary antibodies were used at a 1:10,000 dilution in blocker for 1
hr at room temperature. Blots were washed three times with TBST following incubation
with both the primary and secondary antibodies. Washes were 20 min. each following the
primary antibody and 10 min. each following the secondary antibody.
Chemilumiminescent Peroxidase Substrate-3 was used for visualization following the
manufacturer’s instruction (Sigma). Chemiluminescence was quantified on an Alpha
Innotech HD2 (Fisher) using AlphaEase FC software.
RT-PCR Reactions
Total RNA was extracted using RNeasy Plus (Qiagen). RNA quality and quantity
were analyzed using RNA 6000 Nano Assay and 2100 Bioanalyzer (Agilent). DNase
treatment of each RNA sample was performed prior to RT-PCR using RQ1 RNase-Free
DNase Kit (Promega). For endpoint RT-PCR reverse transcription was carried out using
Superscript ™ II Reverse Transcriptase (Invitrogen). Taq PCR (New England Biolab)
was used for the PCR reaction using following primers, all designed to span the exonexon junction:
mMyc- forward primer (A010) AGCCCCTAGTGCTGCATGAG, reverse primer (A011)
GTTTGCCT CTT CTCCAC AG AC A
mP-casein- forward primer (A012) CCGTTTCTGTCTAAGAGGATTTCC, reverse
primer (A013) GCATGATCCAAAGGTGAAAAGAT
mGAPDH- forward primer (A006) TGAAGCAGGCATCTGAGGG, reverse primer
(A007) CGAAGGT GGAAGAGT GGGAG
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Spyl- forward primer (A091) CCATGGGCTTTAGGGAAAAAC, reverse primer
(A073) TGGCCATAACCTCCTCACAAC
Spyl - forward primer (A092) TCTAAACGCCCCAAAGGACC, reverse primer (A093)
GTC ATAGCC AAAAG ATACTT GT CT GC
hGAPDH- forward primer (A087) GCACCGTCAAGGCTGAGAAC, reverse primer
(A088) GGATCTCGCTCCTGGAAGATG. PCR cycles were optimized to ensure that
end-point measures were on a log-phase scale, in all blots shown 25 amplification cycles
were used. All PCR products were separated on 8% polyacrylamide gel electrophoresis,
visualized on Chemi Genius Bio Imaging System (Syngene) after ethidium bromide
staining using GeneSnap (Syngene) and quantified using Gene Tools (Syngene) software
Mammary Gland Development Assays
Mammary gland tissues were collected from C57BL/6 female mice during
developmental time course. C57BL/6 mice were maintained following the guidelines of
the Association for Assessment of Laboratory Animal Care and the assay carried out as
outlined in University of Tennessee Health Science Center, protocol #1422. Tissues were
either paraffin embedded for immunocytochemistry or flash frozen for use in western
blots or mRNA analysis. Fat pad transplant assays were conducted using BALB/c mice,
which are syngeneic for the HC11 cell line. BALB/c mice were maintained following the
guidelines of the Canadian Council on Animal Care and the assay carried out as outlined
in University of Windsor AUPP #06-19. Stable Spyl-HCl 1 cells and Cntl-HCl 1 cells
(5><105 cells) were injected into the cleared fat pad of 4th pair mammary glands of 22 day
old mice and allowed to grow for 8-16 weeks. Tumor incidence was monitored weekly
after 4 weeks by palpitation of the gland. Whole mount carmine alum staining of
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mammary gland was performed as previously described (Fata et al. 2001). Mammary
gland whole mounts were visualized on a Leica MZFLIII dissecting scope, pictures taken
using Northern Eclipse software. BALB/c mice utilized for lactation studies were bred at
8 weeks post-transplantation and were sacrificed on days 1 or 2 following birth of the
pups. Mammary glands were embedded for sections, flash frozen for RT-PCR analysis or
prepared for whole mount.
Histological Analysis
Mammary glands were harvested, immediately fixed in 4% paraformaldehyde
over night and stained with hematoxylin/eosin as previously described ((Lenferink et al.
2000). Briefly, paraffin-embedded mammary glands were sectioned (6 pm) and stained
with Mayer’s hematoxylin and eosin B-phyloxine (Sigma). IHC was done on mouse
mammary gland tissues over the development time course using Spyl antibody (1:250)
and using IgG staining as a negative control.
Estrogen and Tamoxifen Treatments
Fetal calf serum was treated with charcoal, dextran coated (Sigma) over night at
4C. MCF7 cells were maintained in the medium supplemented with charcoal treated
serum for 5 days prior to estrogen treatment. These cells then were treated with 10 nM
17-P-estradiol (Calbiochem) as well as the vehicle control (DMSO) over the experimental
time course. For tamoxifen treatment, MCF7 cells were treated with 10 nM 4-hydroxytamoxifen (Sigma) and the vehicle control (DMSO) over the same time course in the
presents o f estroid hormones. Cell lysate of representative samples were analyzed on
10% polyacrylamide-SDS gels and transferred to PVDF-PLUS transfer membrane.
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Expression of endogenous Spyl was determined by immunoblotting with Spyl
polyclonal antibody.
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CHAPTER IV

ANALYSIS OF RESULTS
Spyl protein and mRNA levels are tightly regulated during mammary gland
development.
Utilizing a mouse model of mammary gland development, tissue was collected at
various time points during development and prepared for protein and mRNA analysis.
Immunostaining demonstrates that Spyl is primarily localized to the epithelial cells, and
that expression is absent or weak in the myoepithelial cells as well as in adipose tissue
(Figure 1A). Immunostaining of tissues during lactation demonstrate that there is only an
occasional, weakly positive epithelial cell; however low-level expression of Spyl in
adipose cells appears to be maintained. Expression patterns seen by immunostaining are
mimicked by western blot analysis where Spyl protein levels are elevated in early
pregnancy and are dramatically reduced at peak lactation, coinciding with cell
differentiation (Figures IB). Interestingly, at 4 days post-weaning, a period of peak
involution, Spyl expression is upregulated again. These data implicate Spyl in the
proliferative and apoptotic stages of mammary gland development. Figure 1C
demonstrates that this expression is regulated at an mRNA level. Spyl mRNA is elevated
during early pregnancy and is depleted at 15 days pregnancy, a time when the gland
begins to undergo terminal differentiation, as indicated by P-casein expression.
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Figure 1

Spyl protein is tightly regulated in the developing mouse mammary gland.
C57BL/6 female mice were studied over a developmental time-course including mature 4
week virgin mice (Virgin), 6,10, 15, 17.5 days into pregnancy (6 Preg; 10 Preg; 15 Preg;
17.5 Preg), 10 day post-lactation (lactation) and 4 days involution (involution). (A)
Mammary glands were isolated, paraffin embedded and prepared for
immunohistochemistry. Staining was carried out using Spyl antibody or secondary
antibody only as the control (IgG control). (B) Mammary glands were homogenized and
protein extracts were analyzed by 10% SDS-PAGE followed by immunoblotting with
Spyl antibody. Equal protein was loaded in each lane as determined by Bradford protein
assay and confirmed by immunoblotting the same blot with actin antibody. (C)
Mammary glands were homogenized and total RNA extracts were analyzed by RT-PCR
using random hexamer primers for first strand c-DNA generation followed by PCR using
Spyl specific PCR primers. Equal RNA was used as determined by RNA nano assay and
confirmed by equal GAPDH levels in all reactions and P-casein mRNA levels were
utilized as a marker for differentiation.
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Spyl upregulation in the proliferating mammary gland occurs via a MAPK- and c-Mvcdependent signaling mechanism.
Using the HC11 cell system we have determined that Spyl protein (Figure 2A)
and mRNA levels (Figure 2B) are high in proliferating HC11 cells and are drastically
depleted at 3 days post-differentiation, a time period that is coincident with the onset of
P-casein protein expression, as indicated with both P-casein mRNA expression (Figure
2B, lower panel), and luciferase reporter activity (Figure 2C). Cells grown to confluence,
to infer the competency of the cells to respond to differentiation stimuli, do not show any
significant reduction in Spyl expression over loading controls. To investigate the
possible signaling pathways mediating this controlled expression of Spyl we treated
proliferating HC11 cells with a variety of different hormones or inhibitors and studied the
direct effects on Spyl protein expression. Figure 2D demonstrates that treatment with
inducers of differentiation, prolactin and dexamethasone, do not directly down regulate
Spyl protein levels as compared to vehicle (DMSO) alone treatment (upper panel; lanes
1-3). However, treatment with the MAPK inhibitor PD98058 significantly reduced Spyl
protein levels (upper panel; lane 5), suggesting that Spyl expression is dependent on
active MAPK signaling. Levels of Spyl were not altered by SB202474 which is the
negative control for MAPK inhibition studies (upper panel; lane 4).
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Figure 2

Spyl protein is tightly regulated in different developmental stages o f the HC11
cell line. HC11 cells were cultured to confluence and differentiation was induced by
incubation of competence cells for three days in differentiation media. Cells were
analyzed during proliferation (Pro), confluence (Con), day three and day five post
differentiation (D3, D5). (A) Total protein was extracted and analyzed by 10% SDSPAGE followed by immunoblotting with Spyl antibody. Equal protein was loaded in
each lane as determined by Bradford protein assay and confirmed by immunoblotting the
same blot with actin antibody. (B) Total mRNA extracts were analyzed by RT-PCR using
random hexamer primers to generate first strand c-DNA followed by PCR using Spyl
specific PCR primers. Equal RNA was used in each RT-PCR reaction as determined by
RNA nano assay and confirmed by equal GAPDH levels in all reactions. P-casein mRNA
levels were utilized as a marker for differentiation. (C) HC11 cells were transfected in
parallel to experiments described above (A & B). Cells were seeded in triplicate and were
transfected with a vector expressing luciferase behind the P-casein promoter. Luciferase
activity is reported for 3 separate samples from days 1-4 during proliferation (P1-P4), as
well as during confluence (C) and days 3 and 5 post-differentiation (D3, D5). Error bars
reflect the standard error of the mean between triplicate samples. (D) Proliferating HC11
cells were treated with Dexamethasone (DEX), Prolactin, vehicle control (DMSO), lpM
inhibitor control (SB202474) and lpM MAPK inhibitor (PD98058). Total protein was
extracted and analyzed by 10% SDS-PAGE followed by immunoblotting with Spyl
antibody. Equal protein was loaded in each lane as determined by Bradford protein assay
and confirmed by immunoblotting the same blot with actin antibody.
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Expression of c-Myc is involved in processes of growth, neoplasia and apoptosis
(Marcu et al. 1992; Ryan and Bimie 1996). c-Myc expression is tightly regulated in the
mammary gland and reflects a similar pattern of expression as that observed with Spyl;
being downregulated during differentiation, and upregulated during states of proliferation
or during apotosis (Ryan and Bimie 1996; Grolli et al. 1997). Due to these similarities,
and the known involvement of the MAPK signaling pathway upstream of Spyl, we
wished to determine whether Spyl could be a downstream target for c-Myc signaling. To
do this we utilized a Myc-ER™ inducible cell system (Littlewood et al. 1995). Different
estrogen dependent proteins have been fused with the hormone binding domain (HBD) of
estrogen receptor (ER) to create an inducible protein expression system. There are
advantages and disadvantages with ER-HBD fusion proteins. Estrogen is available,
inexpensive and many cell types lack endogenous ER. However, disadvantages persist
with regard to the presence of estrogen in the preferred media and serum and the
inefficiencies which may be related to depletion, using charcoal-dextran treatment.
Additionally, there have been issues with regard to the amount of transcriptional activity
o f the ER-HBD fusion proteins occurring as a result of the hormone binding domain of
ER (Webster et al. 1988; Lees et al. 1989; Tora et al. 1989; Berry et al. 1990; Danielian et
al. 1993; Schuermann et al. 1993). The Myc-ER™ system utilizes a mutant murine ER
(ER™) that no longer binds to estrogen , so it does not exhibit any transactivation
activity, but it binds to tamoxifen (Danielian et al. 1993; Littlewood et al. 1995).
Tamoxifen treatment releases the inhibitory effect of receptor, thereby activating the
fusion protein; c-Myc (Littlewood et al. 1995). The Myc-ER™ mouse embryonic
fibroblast (MEF) cell line stably expresses c-MycER™ chimeric protein; and c-Myc
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activities that are dependent on tamoxifen (Littlewood et al. 1995). Since MEFs do not
express endogenous ER, all the effects of hormone can be attributed to the action of cMyc.

Using MEF cells lacking the Myc-ER™ fusion (Myc-ER™-; left panels) as a
control or the Myc-ER™ MEF cell line (Myc-ER™+; right panels), we addressed
whether c-Myc has a direct effect on Spyl expression. Figure 3A demonstrates that the
Myc-ER™+ cells turn on c-Myc protein after 15 min. of tamoxifen treatment (upper
panels). This figure further demonstrates that Spyl protein levels are elevated
significantly by 30 min. following the induction of c-Myc (middle panels). Next we
wanted to determine whether this induction was occurring at the mRNA level. As seen in
Figure 3B, Spyl mRNA levels accumulate significantly at 1 hr. post-treatment with
tamoxifen. In order to determine whether Spyl induction by c-Myc requires de novo
protein synthesis, mRNA levels of Spyl were monitored through a time course of
tamoxifen treatment in the presence of the protein synthesis inhibitor cyclohexamide.
Even in the absence of de novo protein synthesis Spyl mRNA levels were elevated
following treatment with tamoxifen (Figure 3C; upper panel lanes 1-5). This
accumulation was not a result of the cyclohexamide treatment alone (lanes 6-8). These
results were quantified as described in materials and methods, and data was expressed as
bar graph (Figure 3D). These experiments demonstrate that c-Myc, an established
regulator of mammary gland proliferation, is capable of activating Spyl mRNA and
protein expression. Whether c-Myc is functioning directly as a transcription factor for
Spyl remains to be determined. This exciting correlation between Spyl and the oncogene
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c-Myc emphasizes the importance of understanding how Spyl is regulated during
mammary gland development since it may provide future relevance to the understanding
of breast cancer.
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Figure 3

Spyl protein levels are regulated downstream o f c-Myc. (A) Myc-ER™- MEF
control cells (left hand panels) and Myc-ER™+ MEF cells (right hand panels) were
treated with lOOnM tamoxifen (TAM) and total protein extracts collected at different
time points (Omin, 15min, 30min, 45min, 60min, 90min and 240min). Lysates were
analyzed by 10% SDS-PAGE followed by immunoblotting with c-Myc antibody (upper
panel), Spyl antibody (middle panel). Equal protein was loaded in each lane as
determined by Bradford protein assay and confirmed by immunoblotting the same blot
with Actin antibody (lower panel). (B) Myc-ER™+ MEF cells were cultured and treated
with lOOnM TAM and total mRNA collected at various time points (Ohr, lhr and 4hr).
RT-PCR was performed using random hexamer primers to generate first strand cDNA
followed by PCR using Spyl and GAPDH specific PCR primers. Equal RNA was used in
each RT-PCR reaction as determined by RNA nano assay and confirmed by equal
GAPDH levels in all reactions. (C) Myc-ER™+ MEF cells were cultured and treated
with 50 pg/ml cyclohexamide (CHX) 30 min. prior to TAM treatment as described in
materials and methods. Total mRNA extracts at various time points (Ohr, lhr, 2hr, 3hr
and 4hr) were analyzed by RT-PCR using random hexamer primers to generate first
strand c-DNA followed by PCR using Spyl specific PCR primers. Equal RNA was used
in each RT-PCR reaction as determined by RNA nano assay and confirmed by equal
GAPDH levels in all reactions. Spyl mRNA is present after activation of c-Myc protein
via TAM treatment (lhr, 2hr, 3hr and 4hr) (lanes 2-5). Spyl mRNA is not detectable
before activation of c-Myc protein (0 hr; lane 1). Cyclohexamide (CHX) treatment alone
has no significant effect on Spyl mRNA levels (lanes 6-8). (D) Levels were quantified
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using Synsnap analysis program o f Syngene (Perkin Elmer). X-axis indicates lanes from
Figure 3C and y-axis demonstrates relative Spyl expression.
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The downregulation of Spyl is essential for terminal differentiation
Three different plates of HC11 cells were infected using different batches of
retrovirus as described in materials and methods. 24 individual stable HC11 colonies
were tested for their flag expression ability (Figure 4A). Using stable HC11 cell lines
which over express either flag-tagged Spyl (Spyl-HCl 1) or an empty vector control
(Cntl-HCl 1) (Figure 4B), we sought to determine the effects of preventing Spyl down
regulation on mammary cell differentiation. Here both the control and Spyl expressing
cells were subject to a normal differentiation time course and mRNA was collected from
cells throughout the phases of growth, confluency and differentiation. The control cell
line shows a reduction of Spyl mRNA co-incident with the onset of P-casein expression
at day 2 post-differentiation (D2) and a depletion of detectable mRNA by day 3 postdifferentiation (D3) (Figure 4C). In contrast to this, when Spyl levels are maintained via
a foreign promoter, p-casein expression is barely detectable throughout the remainder of
the differentiation time course (Figure 4D). These results were quantified as described in
materials and methods, and data was expressed as a bar graph (Figure 4E). These results
strongly suggest that the down regulation of Spyl is required for differentiation to occur.
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Figure 4

Abundance o f the Spyl transcript suppresses terminal differentiation. (A) Three
different plates of HC11 cells were infected using different batches of retrovirus. 24
individual stable HC11 colonies were tested for their flag expression ability. Protein
expression was analyzed by 10% SDS-PAGE followed by immunoblotting with flag
antibody (upper panel). Equal protein loading was determined by Bradford protein assay
and confirmed by immunoblotting the same blot with actin (lower panel). (B) Stable flagtagged Spyl over expressing HC11 cells (Spyl-HCl 1) were generated using retroviral
gene transfer technology, an empty flag-empty vector (PLXSN) was also virally infected
to use as a control cell line (Cntl-HCl 1). Following several passages under antibiotic
selection total protein extracts were collected from Spyl-HCl 1 and Cntl-HCl 1 cells.
Protein expression was analyzed by 10% SDS-PAGE followed by immunoblotting with
flag antibody (upper panel) and endogenous Spyl antibody (middle panel). Equal protein
loading was determined by Bradford protein assay and confirmed by immunoblotting the
same blot with actin. (C & D) Total mRNA was collected from Spyl-HCl 1 (D) or CntlHCl 1 (C) cells during proliferation (Pro), confluency (Con), and post-differentiation over
a period of 6 days (D2-D6). Samples were analyzed by RT-PCR using random hexamer
primers to generate first strand cDNA followed by PCR using Spyl (upper panel), (3casein (middle panel) and GAPDH (lower panel) specific primers. Equal RNA was used
in each RT-PCR reaction as determined by RNA nano assay and confirmed by equal
GAPDH levels in all reactions (lower panel). (E) Bands from RT-PCR analysis in parts
C&D above were quantified using the Synsnap analysis program following visualization
on the Syngene Gel Documentation system (Perkin Elmer). P-casein levels were
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normalized with corresponding GAPDH levels and are graphically depicted. The X-;
reflects development time course 4 C & D and the Y-axis indicates relative P-casein
expression.

44

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 4

Actin

Actin

Actin

45

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 4

Spyl

46

—►

P-casein

GAPDH — ►

D

Spyl

P-casein

GAPDH

E

1400
1200
1000

o,
X
0)

0)
3o
PQ

o>

•a
CO

800

■ CntlHCll
■ Spy HC11

600
400

Pi
200

P ro

Con

D2

D3

D4

D5

D6

Development time course

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

47

Interestingly, when cultured to promote acini formation, the Spyl-HCl 1 cells,
unlike the Cntl-HCl 1 counterparts, are not capable of forming acini-like spheroids during
development (Figure 5). Even during confluency Spyl-HCl 1 cells have a propensity to
generate disorganized piles of cells rather than remaining as an organized blanket of cells
such as the Cntl-HCl 1 line (Figure 5; top panel). These data demonstrate that, at a
cellular level, Spyl over expression alters the ability of mammary cells to undergo
normal morphogenesis; thereby preventing the formation of acini.
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Figure 5

Spyl inhibits acini formation and alters cellular morphology. Effects of Spyl
over expression on the ability of HC11 cells to acquire a differentiated morphology was
determined by culturing Cntl-HCl 1 and Spyl-HCl 1 stable cell lines to confluence and
adding differentiation media. Upper panel depicts bright field images of confluent CntlHC11 or Spyl-HCl 1 cells at 40x magnification, lower panels depict cells following
differentiation (40x magnification - middle panel; lOOx magnification - lower panel).
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Spyl overexpression induces precocious locular development in the virgin mammary
gland in vivo
To investigate the effects of Spyl over expression in vivo we took advantage of
the cleared fat pad transplant technique. During this technique the pre-pubertal inguinal
mammary glands are cleared from the TEBs and the remaining fat pad is used as an
injection site. The injected cells use the cleared mammary fat pad as an extra cellular
matrix. To determine the effects of Spyl over expression on mammary gland
morphogenesis in vivo we transplanted the stable Spyl-HCl 1 and Cntl-HCl 1 cells into
the cleared fat pad of syngeneic mice (BALB/c). Carmine alum staining of the whole
mounts from virgin transplanted mice demonstrated that fat-pads injected with SpylHCl 1 cells filled the mammary fat pad at a faster rate and exhibit increased ductal
branching at only 8 weeks post-surgery (Figure 6A; right hand panels) in comparison to
Cntl-HCl 1-transplanted fat pads (Figure 6A; left hand panels). At the end of puberty (10
weeks) Cntl-HCl 1 fat pads were smooth and had small, regular spaced side branches
(Figure 6B- left hand panels); however the Spyl-HCl 1 transplanted fat pads showed
extensive alveolar development of the type that is normally associated with hormonal
stimulation during pregnancy (Figure 6B; right hand panels).
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Figure 6

Spyl over expression induces precocious lobular development in the virgin
mammary gland in vivo. Spyl-HCl 1 and Cntl-HCl 1 stable cells (0.5xl06 cells) were
injected into the cleared fat pads of the 4th inguinal mammary glands of virgin, 22 day
old syngenic BALB/c mice. Whole mounts of several transplanted glands were analyzed
using carmine alum staining at different time points during puberty. (A) At 8 weeks post
surgery, Spyl-HCl 1 cells fill the cleared mammary fat pads completely (right panel). At
this stage of mammary gland development, Spyl-HCl 1 injected glands also demonstrate
increased ductal branching in compare to Cntl-HCl 1 cells injected glands (left panel).
(B) At 10 weeks post-transplantation Spyl-HCl 1 injected glands demonstrate enhanced
alveolar development and increased ductal side branching (right panel); however CntlHCl 1 injected glands show regular spaced side branches (left panel).
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Spyl overexpression prevents lactogenesis in the mature mammary gland in vivo
During puberty, the rudimentary ductal network of quiescent epithelial cells in the
immature mouse mammary gland rapidly proliferates in response to increased production
o f pubertal hormones and ductal morphogenesis occurs. During pregnancy, a second
round of proliferation followed by differentiation induces alveolar morphogenesis to form
the secretory epithelium responsible for milk production. To study the consequences of
Spyl over expression on alveolar morphogenesis, whole mounts from two day lactating
glands were examined. Whole mount staining of the two transplanted glands
demonstrated that Cntl-HCl 1-injected fat pads had morphologically normal ductal and
alveolar-like structures (Figure 7A). However, fat-pads injected with Spyl-HCl 1 cells
demonstrated abnormal morphology; the luminal space was decreased substantially and
the cells do not look fully differentiated. The alveolar space is not as big and open as it is
in the wild type gland (Figure 7B).
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Figure 7

Spyl over expression prevents lactogenesis in the mature mammary gland in vivo.
Spyl-HCl 1 and Cntl-HCl 1 stable cells (0.5xl06 cells) were injected into the cleared fat
pads of the 4th inguinal mammary glands of virgin, 22 day old syngenic BALB/c mice.
Whole mounts of 2 days lactating transplanted glands were analyzed after carmine alum
staining at different magnifications. (A) Cntl-HCl 1 injected glands contain
morphologically normal ductal and alveolar structures which represent the fully
differentiated glands at lactating stage of mammary gland development. (B) Spyl-HCl 1
injected glands demonstrate more condensed ductal structures and abnormal alveoli.
Abnormal alveolar structures in these glands appear undifferentiated and lack organized
acini.
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Spyl over expression induces mammary tumorigenesis in vivo
By 16 weeks post-transplantation significantly large tumors were visibly detected
on the side of each mouse that had been transplanted with Spyl-HCl 1 cells, with no
visible tumor occurring on the control gland side of the animal that had been transplanted
with Cntl-HCl 1 cells (100% incidence; n=4) (Figure 8A). When dissected out all fatpads injected with Spyl-HCl 1 cells were larger in size and had numerous large solid
mammary tumors (Figure 8B; right hand panel), while all Cntl-HCl 1-injected fat pads
were smaller and look completely normal with no visible outgrowths (Figure 8B; left
hand panel). This is extremely exciting data, as the tumor incidence in virgin, young
BALB/c mouse strain is known to be very low (Bult et al. 2000; N af et al. 2002; Krupke
et al. 2005; Begley et al. 2007). To gain statistical significance and to control for
retrovirus random integration in genome, 22 more mammary fat-pad transplants using 4
different Spyl-HCl 1 stable colonies have been performed and are awaiting analysis.
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Figure 8

Spyl over expression induces mammary tumorigenesis in vivo. Spyl-HCl 1 and
Cntl-HCl 1 stable cells (0.5x106 cells) were injected into the cleared fat pads of the 4th
inguinal mammary glands of virgin, 22 day old syngenic BALB/c mice. (A) 16 weeks
after the fat pad transplants, mammary glands injected with Spyl-HCl 1 cells produced
large outgrowths; while the Cntl-HCl 1 glands looked normal. (B) Mammary glands were
dissected and mammary tumors were observed only in Spyl-HCl 1 injected glands (left
panel) Cntl-HCl 1 injected glands were smaller in size and did not represent any form of
outgrowths (right panel).
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Estrogen stabilizes Spyl protein levels, but has no significant effect on Snvl mRNA
We utilized the MCF7 cell line as a model system to study estrogen affects on
Spyl protein and mRNA regulation. MCF7 cells are responsive to estrogen treatment as
they express ER. In order to deplete the steroid hormones from MCF7 cells medium prior
to the estrogen treatment, fetal calf serum was treated with charcoal. To activate the
estrogen pathway, MCF7 cells were maintained in the medium supplemented with
charcoal treated serum for 5 days and then treated with 10 nM estrogen as well as the
vehicle control (DMSO) over the experimental time course. In order to inhibit the
estrogen pathway, MCF7 cells were treated with 10 nM tamoxifen and the vehicle control
(DMSO) over the same time course in the presence of estroid hormones (Osborne et al.
1983; Sutherland et al. 1983a; Sutherland et al. 1983b). Our data shows that estrogen
treatment cause abundance of Spyl at protein level and this effect is inhibited by
tamoxifen, which is a specific estrogen pathway inhibitor (Figure 9A and 9B).
Interestingly, estrogen treatment does not have a significant effect on Spyl mRNA level
(Figure 9C). This data suggests that estrogen stabilizes Spyl protein levels. These
findings are very important as we and others have shown that Spyl protein levels are
elevated in many aggressive forms of cancer, including invasive ductal carcinoma of the
breast (Zucchi et al. 2004) and breast cancer cell lines, but not normal cell lines (Figure
10). Currently our group is studying Spyl protein stability after estrogen treatment using
pulse chase analysis and we have initiated a large scale study on normal and cancerous
breast tissues to compare both protein and mRNA levels of Spyl and possible signaling
pathways.
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Figure 9

Estrogen treatment upregulates Spyl protein levels, but not Spyl mRNA levels.
(A) MCF7 cells were cultured in charcoal treated media for 5days and then treated with
estrogen (E2) as described in materials and methods. Total protein extracts at different
time points (Ohr, 3hr, 7hr, lOhr, 13hr, 26hr and 50hr) were analyzed by 10% SDS-PAGE
followed by immunoblotting with Spyl antibody (upper panel). Equal protein was loaded
in each lane as determined by Bradford protein assay and confirmed by immunoblotting
the same blot with beta actin (lower panel). Spyl protein abundance is observed after
estrogen (E2) treatment. (B) MCF7 cells were cultured and treated with TAM as
described in materials and methods. Total protein extracts at different time points (Ohr,
3/4hr, lhr, 3hr, 6hr, 9hr, 12hr, 24hr and 48hr) were analyzed by 10% SDS-PAGE
followed by immunoblotting with Spyl antibody (upper panel). Equal protein was loaded
in each lane as determined by Bradford protein assay and confirmed by immunoblotting
the same blot with actin (lower panel). Spyl protein accumulation is not observed
through out the treatment time course, after TAM treatment. (C) MCF7 cells were
cultured in charcoal treated media for 5days and then treated with estrogen (E2) as
described in materials and methods. Total mRNA extracts at various time points (Ohr,
3hr, 7hr, lOhr, 13hr, 26hr and 50hr) were analyzed by RT-PCR using random hexamer
primers to generate first strand c-DNA followed by PCR using Spyl specific PCR
primers (upper panel). Equal RNA was used in each RT-PCR reaction as determined by
RNA nano assay and confirmed by equal GAPDH levels in all reactions (lower panel).
Estrogen (E2) has no significant effect on Spyl mRNA levels.
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Figure 10

Spyl protein levels are elevated in breast cancer cell lines. MCF7 cells, HTB126
cells and HTB125 cells were cultured in their specific growth media. Total protein
extracts o f three different proliferating cell lines were analyzed by 10% SDS-PAGE
followed by immunoblotting with Spyl antibody (upper panel). Equal protein was loaded
in each lane as determined by Bradford protein assay and confirmed by immunoblotting
the same blot with actin (lower panel). Spyl protein abundance is clearly observed in
cancerous cell lines (MCF7 and HTB126), but not in non cancerous cell line (HTB125).
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CHAPTER V
CONCLUSIONS AND RECOMMENDATIONS
Discussion and Future Directions
A more clear understanding of the processes regulating mammary gland
development provides information about essential cellular decisions involved in normal
growth, proliferation, migration, branching, invasion, differentiation and apoptosis.
Elucidating these key pathways may provide insight to prevent, detect and treat different
disorders, including proliferation disorders such as cancer. Recently, a SAGE analysis
study revealed Spyl as one of the genes which is elevated in invasive ductal carcinoma of
the breast (Zucchi et al. 2004). Our research supports these findings; we have
demonstrated that Spyl protein levels are elevated in the cancerous cell lines in compare
to non-cancerous cell lines and that Spyl expression is tightly regulated during normal
mammary gland development at both protein and mRNA level. Importantly, we have
demonstrated that Spyl levels are naturally elevated during proliferative stages of
mammary gland development. Through the establishment of stable HC11 cell lines that
overexpress Spyl, we have been able to study the consequences of Spyl overexpression
on HC11 cell differentiation as well as mammary gland development. Using P-casein as a
marker for mammary cell differentiation, we showed that Spyl overexpression
suppresses HC11 cell differentiation in culture. To study different stage of mammary
gland In vivo, we used mouse mammary gland cleared fat pad transplant technique.
Different experiments on transplanted mice have revealed that Spyl overexpression
increases the rate of ductal morphogenesis during puberty; however at the end of puberty
Spyl-HCl 1 injected glands showed increased ductal side branching along with alveolar
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morphogenesis as compared to Cntl-HCl 1 injected glands. This data suggest that Spyl
overexpression induces precocious lobular development in the virgin mammary gland in
vivo as alveolar morphogenesis is known to be one of the mammary gland characteristics
during pregnancy. Other studies have shown similar effects on mammary gland
development when overexpressing ERa or down regulating p27 (Muraoka et al. 2001;
Mallepell et al. 2006). Spyl is known to play a key role in the down regulation of p27
(Porter et al. 2003), and this current work has implicated that Spyl expression may lay
downstream of ERa stimulation (Figures 9 and 10).
In addition, using the HC11 stable cell lines both in vitro and in vivo assays have
supported that the down regulation of Spyl protein levels is an essential event to support
terminal differentiation and alveolar development of the mammary gland. Among
different stage of mammary gland development, the final stage of alveolar morphogenesis
(herein referred to as lactogenesis) was abrogated by constitutive Spyl overexpression. It
is known that lactogenesis, as represented by a full term pregnancy, confers a significant
protection against breast cancer when it occurs in the young animal or human (Kelsey
and Gammon 1990). The fact that Spyl overexpression disrupts lactogenesis can further
implicate Spyl in the initiation of carcinogenesis.
At approximately 16 weeks post-transplantation Spyl overexpressing glands
displayed large solid tumors in 100% of mice transplanted to date (n=4). The importance
o f this data is compounded by the fact that tumor incidence in the young, virgin BALB/c
mouse strain is known to be very low (Bult et al. 2000; Naf et al. 2002; Krupke et al.
2005; Begley et al. 2007). This is the first evidence for a direct role for Spyl in
tumorigenesis. More studies are required to determine statistical numbers with regard to
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the penetrance of Spyl in tumorigenesis. We have since performed 22 additionally fatpad transplants using 4 different Spyl-HCl 1 stable colonies to gain statistical
significance and also to control for retrovirus integration in the genome.
We have also investigated Spyl upstream signaling pathways during mammary
gland development using the HC11 cell model system. Epidermal growth factor (EGF),
one o f the main components of the HC11 cell growth media and a component which is
absent in the HC11 cell differentiation media, plays an essential role during development
o f this cell line. (Schroeder and Lee 1998; Sebastian et al. 1998) It is well established that
EGF activates different signaling pathways such as the MAPK pathway (Boonstra et al.
1995). Our data suggests that Spyl protein levels are regulated, at least in part, by the
MAPK pathway as Spyl is downregulated after MAPK inhibition. Other studies have
shown that Spyl induced oocyte maturation requires the activation of MAPK and
injection of Spyl into oocytes results in the activation o f the MAPK pathway
(Lenormand et al. 1999). Collectively these data suggest a positive feedback loop
between Spyl and the MAPK pathway. One of the known targets of MAPK pathway is cMyc and c-Myc is known to be an important regulator of mammary gland development.
(Alvarez et al. 1991; Liu et al. 1996) Expression of c-Myc promotes growth, neoplasia
and apoptosis (Marcu et al. 1992; Ryan and Bimie 1996). Furthermore, abnormal c-Myc
expression in the mammary gland results in formation of mammary tumors
(Schoenenberger et al. 1988; Welm et al. 2005). c-Myc expression is tightly regulated in
the mammary gland; it is up regulated during proliferation, apoptosis, and downregulated
during differentiation (Ryan and Bimie 1996; Grolli et al. 1997). Interestingly, we have
observed that expression of Spyl mimics the expression profile of c-Myc during
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mammary gland development. This correlation had provided the impetus for us to
examine c-Myc as an upstream regulator for Spyl. We have determined that both Spyl
protein and mRNA levels are elevated after c-Myc induction and this has suggested that
c-Myc is indeed an upstream regulator for Spyl. This has stimulated the hypothesis that
the regulatory effects of c-Myc on Spyl during mammary gland development and
tumorogenesis occurs via activation of MAPK pathway; this link is currently something
that we are investigating both in vitro and in vivo. We have further determined that up
regulation of Spyl mRNA by c-Myc does not rely on de novo protein synthesis this
suggests that c-Myc is functioning directly as a transcription factor for Spyl. We have
analyzed the Spyl predicted promoter region for putative c-Myc binding sites and found
c-Myc binding sites. Further study is required to definitely determine whether c-Myc is
functioning to directly regulate the transcription o f Spyl during mammary gland
development. As mentioned previously, we and others have determined that Spyl protein
levels are elevated in many aggressive forms of cancer, including invasive ductal
carcinoma o f the breast as well as many breast cancer cell lines (Zucchi et al. 2004).
Using the breast cancerous cell line, MCF7 cells we have demonstrated that estrogen is
capable of stabilizing Spyl protein levels; however this has no significant effect on Spyl
mRNA levels. Currently our group is studying Spyl protein stability after estrogen
treatment using pulse chase analysis and we have initiated a large scale study on normal
and cancerous breast tissues to compare both protein and mRNA levels of Spyl and
possible signaling pathways.
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APPENDICES
APPENDIX A
List of Abbreviations
APC

anaphase promoting complex

CAK

cyclin activating kinase

CDK

cyclin dependent kinase

CHX

cyclohexamide

CKI

CDK inhibitor

CPE

cytoplasmic polyadenylation element

CPEB

cytoplasmic polyadenylation element binding

CPT

camptothecin

E2

estrogen

EGF

epidermal growth factor

ER

estrogen receptor

GO

GapO

G1

Gapl

G2

Gap2

GSK-3|3

glycogen synthase kinase-3 P

GVBD

germinal vesicle break down

HBD

hormone binding domain

HU

hydroxyurea

JAK

Janus Kinase

M

Mitosis
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MAPK

mitogen activated protein kinase

MAPKKK

MAP kinase kinase kinase

MEF

mouse embryonic fibroblast

MPF

maturation promoting factor

PBE

Pumilio 2-Binding Elements

PKA

protein kinase A

RINGO

Rapid Inducer of G2/M Ooctye Maturation

S

Synthesis

SAGE

serial analysis of gene expression

ScpPirCP

ubiquitin ligase pTrCP

SCFSkP2

Skp, Cullin, F-box containing complex

siRNA

small interfering RNA

S/R Box

Speedy/RINGO box

STAT

signal transducers and activators of transcription

TAM

tamoxifen

TEB

terminal end bud

Thr

threonine

Tyr

tyrosine

X-RINGOsp

X-RINGO small and processed

X-Spyl

Xenopus-SpyX

UPS

ubiquitin proteasome system

UV

ultraviolet irradiation
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